PR88321

MUMBAI, India, 02 March 2021 /PRNewswire=KYODO JBN/ --

    Cipla Limited (BSE: 500087); (NSE: CIPLA EQ) (hereinafter referred to as

"Cipla") today announced that it has received final approval for its

Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from

the United States Food and Drug Administration (U.S. FDA).

    Cipla's Sumatriptan Nasal Spray USP, 20 mg is an AB-rated generic

therapeutic equivalent version of GlaxoSmithKline's Imitrex(R) Nasal Spray.  

    Imitrex(R) Nasal Spray is a serotonin (5-HT1B/1D) receptor agonist

(triptan) indicated for acute treatment of migraine with or without aura in

adults.

    According to IQVIA (IMS Health), Imitrex(R) Nasal Spray 20mg and its

generic equivalents had US sales of approximately $53.3M for the 12-month

period ending  December 2020.

    About Cipla:

    Established in 1935, Cipla is a global pharmaceutical company focused on

agile and sustainable growth, complex generics, and deepening portfolio in our

home markets of India, South Africa, North America, and key regulated and

emerging markets. Our strengths in the respiratory, anti-retroviral, urology,

cardiology, anti-infective and CNS segments are well-known. Our 46

manufacturing sites around the world produce 50+ dosage forms and 1,500+

products using cutting-edge technology platforms to cater to our 80+ markets.

Cipla is ranked 3rd largest in pharma in India (IQVIA MAT December' 20), 3rd

largest in the pharma private market in South Africa (IQVIA MAT December'20),

and is among the most dispensed generic players in the U.S. For over eight

decades, making a difference to patients has inspired every aspect of Cipla's

work. Our paradigm-changing offer of a triple anti-retroviral therapy in

HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged

as having contributed to bringing inclusiveness, accessibility and

affordability to the centre of the HIV movement. A responsible corporate

citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose

of 'Caring for Life' and deep-rooted community links wherever it is present

make it a partner of choice to global health bodies, peers and all

stakeholders. For more, please visit www.cipla.com [http://www.cipla.com/] , or

click on Twitter [https://twitter.com/Cipla_Global], Facebook

[https://m.facebook.com/Cipla/], LinkedIn

[https://www.linkedin.com/company/cipla]

    Logo: https://mma.prnewswire.com/media/947146/Cipla_Logo.jpg

    Source: Cipla